Trials / Conditions / NMO Spectrum Disorder

NMO Spectrum Disorder

25 registered clinical trials studyying NMO Spectrum Disorder — 12 currently recruiting.

Status	Trial	Sponsor	Phase
Withdrawn	A Phase IIb Study of Nabiximols for Spasticity Due to Neuromyelitis Optica Spectrum Disorders NCT05974293	Michael, Levy M.D.,Ph.D.	Phase 2
Not Yet Recruiting	Tongji NADs Cohort NCT07333196	Tongji Hospital	—
Recruiting	Efficacy and Safety of Transcranial Temporal Interference Stimulation (tTIS) for Neuropathic Pain in Neuromyel NCT07377305	Tang-Du Hospital	N/A
Recruiting	Monoclonal Antibody-Based Therapies for AQP4-Positive NMOSD NCT06885957	Tongji Hospital	—
Recruiting	Safety and Efficacy of BAFF-R CART for Refractory Neuroimmune Diseases NCT07022197	Tianjin Medical University General Hospital	Phase 1 / Phase 2
Withdrawn	A Study of RD06-04 in Patients With Active Autoimmune Diseases NCT06548620	Nanjing Bioheng Biotech Co., Ltd.	EARLY_Phase 1
Not Yet Recruiting	FcRn Antagonists (Efgartigimod) for Acute NMOSD Attack NCT06497374	Tianjin Medical University General Hospital	Phase 2
Recruiting	Clinical Impact Through AI-assisted MS Care - A Retrospective Multi-center Observational Study. NCT06280755	icometrix	—
Completed	ACT with NMOSD Patients and Caregivers Pilot Study NCT05840055	Thomas Jefferson University	N/A
Recruiting	Efficacy and Safety of Baricitinib in Neuromyelitis Optica Spectrum Disorders NCT05792462	Tianjin Medical University General Hospital	Phase 1 / Phase 2
Active Not Recruiting	Safety and Efficacy of Daratumumab in Patients With Anti-Aquaporin 4 Antibody Positive Neuromyelitis Optica Sp NCT05403138	Tianjin Medical University General Hospital	Phase 2 / Phase 3
Unknown	Sensitivity and Specificity of TSA-CBA for Autoantibodies Against Neural Antigen Determination NCT05414890	Beijing Tiantan Hospital	—
Completed	A Study of LP-168 in Healthy Volunteers NCT05432713	Guangzhou Lupeng Pharmaceutical Company LTD.	Phase 1
Recruiting	Clinical Study of B001 Injection in Subjects With Neuromyelitis Optic Spectrum Disorder (NMOSD) NCT05145361	Shanghai Pharmaceuticals Holding Co., Ltd	EARLY_Phase 1
Recruiting	China National Registry of Neuro-Inflammatory Diseases NCT05154370	Beijing Tiantan Hospital	—
Completed	Efficacy and Safety of Belimumab in Neuromyelitis Optica Spectrum Disorders NCT05154734	Tianjin Medical University General Hospital	Phase 1 / Phase 2
Recruiting	Biorepository and Registry for Plasma Exchange Patients NCT05004493	Charles M Knudson	—
Unknown	Imaging Evaluation of Central Nervous Autoimmune Diseases NCT04822623	Qilu Hospital of Shandong University	—
Recruiting	National, Multicentric Registry Study on Neuroimmunological Diseases in China NCT06443333	Xuanwu Hospital, Beijing	—
Completed	Epidemiological Characteristics of COVID-19 in Patients With MS or NMO NCT04355611	Assistance Publique - Hôpitaux de Paris	—
Completed	A Study of HBM9161 in NMOSD Patients NCT04227470	Harbour BioMed (Guangzhou) Co. Ltd.	Phase 1
Completed	Monitoring of Azathioprine Metabolite Concentrations and Cytokine Levels in Neuromyelitis Optica Spectrum Diso NCT05896605	First Affiliated Hospital of Guangxi Medical University	Phase 4
Withdrawn	Autologous Transplant To End NMO Spectrum Disorder NCT03829566	Northwestern University	Phase 2 / Phase 3
Recruiting	Clinical and Imaging Cohort of Neuroinflammation Diseases in China (CLUE) NCT04106830	Beijing Tiantan Hospital	—
Completed	Pediatric NMOSD Observational Study NCT03766347	Mayo Clinic	—